SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending following news of a strategic manufacturing partnership aimed at significantly reducing production costs and expanding capacity, which has driven substantial intraday stock volatility. The community is actively discussing the stock's low float and high trading volume, fueling speculation about a potential short squeeze and anticipating further upward movement as it tests key resistance levels. This partnership is seen as a crucial step for scaling their fingerprint drug screening technology ahead of anticipated future market expansion.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending due to recent discussions surrounding its integration as a fuel-discount token within the EzFill app, generating buzz about its expanding utility. The community is sharply divided, with many anticipating significant future appreciation from multi-year lows and viewing it as "digital silver," while others express frustration over its recent price action and struggle to overcome key resistance levels.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is currently a focal point for year-end tax loss selling, leading to sharp price movements and a polarized community discussion. Many foresee further declines for the meme coin, while a resilient group of long-term holders views the current dip as a strategic accumulation opportunity for future crypto cycles, with eyes on a potential rally in 2026.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending significantly following the FDA approval of NEREUS, marking the first new pharmacologic treatment for motion-induced vomiting in over four decades. The community is actively discussing the drug's potential beyond motion sickness, particularly its vast opportunity in addressing GLP-1 induced nausea, which many see as a transformative revenue driver for the company. With analysts raising price targets and whispers of potential buyout interest, investors anticipate continued upside as the market fully prices in this key regulatory win and the company's robust pipeline.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESH Acquisition Corp (ESHA) is trending within a volatile low-float SPAC sector, fueled by discussions surrounding its extremely tight share float and high insider ownership. The community is actively debating its potential for rapid price movement and a short squeeze, drawing comparisons to other recently surging SPACs as new utility via a planned reward token is also highlighted.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics (CORT) is trending with significant volatility after receiving an FDA Complete Response Letter for its relacorilant drug, triggering a sharp decline in shares. The community is fiercely divided, with many calling the sell-off an overreaction given the company's existing profitable drug and deep pipeline, while others foresee further downside following analyst downgrades and a need for more clinical evidence. This binary regulatory event has intensified speculation, as investors weigh potential recovery against lingering uncertainty.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending following the FDA's acceptance and priority review of AXS-05 for Alzheimer's disease agitation, alongside positive feedback supporting an upcoming NDA for AXS-12 in narcolepsy. The market is reacting strongly to this dual pipeline advancement, with community members expressing high optimism and noting significant short-covering as a key driver of the momentum.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after a competitor's drug for Cushing's syndrome received a regulatory setback from the FDA, which the community views as a significant advantage for Xeris's approved treatment, Recorlev. This development is seen as clearing the path for Recorlev to gain market share, fueling discussions among investors about the company's long-term growth potential and undervaluation, supported by positive analyst outlooks.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is highly active following the CME Group's recent, repeated increases in margin requirements for silver futures, sparking intense debate among traders who see it as a desperate measure to control a surging market. This volatility is further fueled by conflicting narratives around impending Chinese silver export restrictions and the growing disconnect between paper and physical prices. The community is sharply divided between those predicting a massive short squeeze driven by industrial demand and global supply shifts, and those anticipating a significant pullback.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as its community intensely debates future prospects amid persistent price challenges. Significant anticipation surrounds potential regulatory clarity from the "Clarity Act" and major developments like integrations with large retailers and payment networks. Despite widespread frustration over price action, many remain bullish, highlighting AMP's core utility in secure digital payments and its existing merchant adoption as crucial for eventual upside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Needham maintained a “Buy” rating with a $300 price target for Reddit</li><li>The firm says Reddit is the fastest-growing company in its coverage.</li><li>Needham added Reddit to its ‘Conviction buy’ list, replacing Roku.</li></ul>Reddit’s stock (<a href="https://stocktwits.com/symbol/RDDT">RDDT</a>) was in the spotlight on Tuesday after analysts at Needham named it as its top pick for 2026 and added the stock to its ‘Conviction buy’ list by replacing Roku. Needham maintained its “Buy” rating, with a $300 price target, citing the platform’s 100% human-created content as the key differentiator.According to TheFly, analysts at Needham believe Reddit’s authentic content optimizes trust and value for large language models (LLMs), making it attractive.They added that Reddit already generates over $100 million per year in fees from OpenAI and Google's Gemini, and this could double with Anthropic and Perplexity fees.Needham also noted that Reddit is the fastest-growing company in its coverage, while its Performance Ads offer "full-funnel ad solutions" and a larger share of ad budgets.<h2 class="st-heading-2">OpenAI, Google AI Content Licensing Deal</h2>Reddit has been partnering with OpenAI since 2024 to bring its content to ChatGPT under the deal. In this arrangement, both OpenAI and ChatGPT use Reddit’s application programming interface, which also distributes Reddit's content. As part of the deal, OpenAI also became Reddit's advertising partner.Before its IPO, Reddit had also struck an AI content licensing deal with Google worth about $60 million per year, according to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/technology/reddit-ai-content-licensing-deal-with-google-sources-say-2024-02-22/">report</a> from Reuters. The deals underscored the company's efforts to generate more revenue amid fierce competition from other major players, such as Meta’s Facebook.<h2 class="st-heading-2">AI Bet Paying Off</h2>Reddit has been seeing its AI-powered advertising tools attract more marketing spending on the platform. During the third quarter (Q3) earnings call, its Chief Operating Officer, Jen Wong, told analysts that Reddit’s total active advertiser count expanded by over 75% year-over-year.It has prompted Reddit to forecast current-quarter revenue at the higher end of analyst estimates, according to Fiscal.ai data. The company expects fourth quarter revenue (Q4) to be between $655 million and $665 million, in line with analyst projections of $665 million.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around the RDDT trended in “bearish” territory amid “normal” message volume.&nbsp;<figure class="image"><img style="aspect-ratio:643/71;" src="https://news.stocktwits-cdn.com/rddt_PNG_ec1f193863.webp" alt="Retail sentiment around the RDDT trended in “bearish” territory amid “normal” message volume. " width="643" height="71"></figure> For updates and corrections, email newsroom[at]stocktwits[dot]com.Editor's Note: The story has been updated to reflect the correct name of Reddit's COO.

In this photo illustration, a Reddit logo is seen displayed on a smartphone with an Artificial Intelligence (inscriptions) in the background. (Photo Illustration by Avishek Das/SOPA Images/LightRocket via Getty Images)

Why Reddit Is Needham’s ‘Top Pick’ For 2026 After A 40% Surge

Analysts cite Reddit’s 100% human-created content and fast-growing ad platform as key drivers of future revenue.

Why Reddit Stock Is Needham’s ‘Top Pick’ For 2026 After A 40% Surge

Equity

Should Vanguard Mid-Cap Growth ETF (VOT) Be on Your Investing Radar?

DoorDash (DASH) shares surged 9% in premarket trading on Thursday after&nbsp;the company reported strong quarterly results and a forecast, but retail investors warned of potential profit booking in the regular session.Shares were even higher in Wednesday's after-market trading, and a retail trader on Stocktwits <a href="https://stocktwits.com/firehorse/message/624039946">noted</a> at the time that, should the gains hold, DoorDash would be valued at par with&nbsp;<a href="https://stocktwits.com/symbol/FDX">FedEx (FDX)</a> and&nbsp;<a href="https://stocktwits.com/symbol/UPS">United Parcel Service (UPS)</a> combined.As of the last close, DoorDash was valued at $109.36 billion, while the combined market cap of the two legacy courier companies was $126.46 billion, according to TradingView.On Stocktwits, the retail sentiment for DASH shifted to 'extremely bullish' as of early Thursday, from 'bullish' the previous day, with message volume rising over 200% in the past 24 hours.Users generally posted&nbsp;positive comments about the results, which exceeded Wall Street's expectations, albeit with a cautionary note."$DASH Huge profit taking at open just like last time. This will dump 10 points in seconds," one said.<stembedurl>https://stocktwits.com/Skies88/message/624056931</stembedurl>"Parabolic moves get noticed and punished at open. Take your profits and run!" another said.<stembedurl>https://stocktwits.com/Skies88/message/624058249</stembedurl>DoorDash reported second-quarter results that beat the Street's expectations for revenue, adjusted profit, and gross merchandise value (GMV), and also forecast Q3 GMV higher than expectations.The results show robust demand for food delivery services, particularly in its main markets such as the U.S. and Canada. To its credit, DoorDash has also broadened its delivery offerings beyond food recently to include groceries, alcohol, electronics, and beauty items, helping it drive up orders.Rival Uber Eats' parent Uber (UBER.N) also forecast a strong third quarter earlier in the day, banking on robust demand for ride-hailing and deliveries.The results come close on the heels of major acquisitions. In May, DoorDash acquired British food delivery startup Deliveroo for about $3.9 billion and restaurant technology company SevenRooms for $1.2 billion.<a href="https://stocktwits.com/symbol/DASH">DoorDash’s shares</a> have risen 54% year-to-date. If the pre-market move holds in Thursday’s session, it would be the stock’s best performance in about four months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

(Photo Illustration by Emily Dulla/Getty Images for DoorDash)

DoorDash Could Be Nearly Worth FedEx And UPS Combined If Premarket Surge Holds: Retail Cheers Strong Q2, Outlook

DoorDash shares were up 9% premarket; however, some retail investors warned of potential profit-booking ahead of the market open.

VOT
Vanguard Mid-Cap Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VOT News

VOTVanguard Mid-Cap Growth ETF